Ko-Med Centra Kliniczne Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at Ko-Med Centra Kliniczne Sp. z o.o. is exploring innovative antibody‑based treatments for autoimmune conditions, aiming to reduce disease activity in patients who have not responded to standard therapies.
- Evaluation of anti‑TNFR1 small‑molecule inhibitor
- Dose‑response study of a bispecific antibody
- Safety assessment of novel immunomodulators
With 14 investigators involved, the site emphasizes advancing therapeutic options for Rheumatoid arthritis and related immune disorders.
Musculoskeletal Diseases
Clinical investigations focus on improving outcomes for patients with inflammatory joint disease by testing new agents alongside existing disease‑modifying drugs.
- Combination therapy efficacy with conventional DMARDs
- Impact on functional mobility and pain relief
- Long‑term safety monitoring in moderate to severe cases
The program highlights the potential of targeted biologics to address unmet needs in rheumatoid arthritis management.
Nutritional and Metabolic Diseases
Studies are designed to evaluate cardiovascular protection strategies in adults at high risk, testing how advanced lipid‑lowering agents can lower the incidence of heart attacks and strokes.
- Assessment of cardiovascular event reduction
- Effect on cholesterol and triglyceride levels
- Evaluation of arterial revascularization outcomes
By targeting cardiovascular risk, the site aims to complement optimized standard therapy with innovative treatments such as evolocumab.
Respiratory Tract Diseases
The facility conducts trials to prevent symptomatic infection from emerging viral variants, focusing on pre‑exposure prophylaxis with monoclonal antibodies.
- Prophylactic efficacy against diverse SARS‑CoV‑2 strains
- Variant‑specific protection analysis
- Safety evaluation in a sentinel cohort
Research includes the novel antibody candidate AZD3152, aiming to reduce the burden of COVID-19 in vulnerable populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 42 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Arrowhead Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ko-Med Centra Kliniczne Sp. z o.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 2 | Unknown | 2023-06-21 | 2023-11-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.